Oliwia Majchrzak

Mrs. Oliwia Majchrzak

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Marija PetrovicMarija Petrovic
Marija Petrovic
Alexandre PorcelloAlexandre Porcello
Alexandre Porcello
STStoyan Tankov
Stoyan Tankov
OMOliwia Majchrzak
Oliwia Majchrzak
MKMartin Kiening
Martin Kiening
Olivier JordanOlivier Jordan
Olivier Jordan
Anti-tumor responses can be achieved via the stimulation of the immune system, a therapeutic approach called cancer immunotherapy. Many solid tumor types are characterized by the presence of immune-suppressive tumor-associated macrophage (TAMs) cells within the tumor microenvironment (TME). Moreover, TAM infiltration is strongly associated with poor survival in solid cancer patients and hence a low responsiveness to cancer immunotherapy. Therefore, 2′3′ Cyclic GMP-AMP (2′3′ cGAMP) was employed for its ability to shift macrophages from pro-tumoral M2-like macrophages (TAM) to anti-tumoral M1. However, cGAMP transfection within macrophages is limited by the molecule’s negative charge, poor stability and lack of targeting. To circumvent these barriers, we designed nanocarriers based on poly(amidoamine) dendrimers (PAMAM) grafted with D-glucuronic acid (Glu) for M2 mannose-mediated endocytosis. Two carriers were synthesized based on different dendrimers and complexed with cGAMP at different ratios. Orthogonal techniques were employed for synthesis (NMR, ninhydrin, and gravimetry), size (DLS, NTA, and AF4-DLS), charge (DLS and NTA), complexation (HPLC-UV and AF4-UV) and biocompatibility and toxicity (primary cells and hen egg chorioallantoic membrane model) evaluations in order to evaluate the best cGAMP carrier. The best formulation was selected for its low toxicity, biocompatibility, monodispersed distribution, affinity towards CD206 and ability to increase M1 (STAT1 and NOS2) and decrease M2 marker (MRC1) expression in macrophages.

Verified
Journal Article
Open access
PDF file
Marija PetrovicMarija Petrovic
Marija Petrovic
OMOliwia Majchrzak
Oliwia Majchrzak
RMRihana Amreen Mohamed Hachime Marecar
Rihana Amreen Mohamed Hachime Marecar
ALAnnick C. Laingoniaina
Annick C. Laingoniaina
PWPaul R Walker
Paul R Walker
STStoyan Tankov
Stoyan Tankov
Glioblastoma (GBM) is an aggressive brain cancer with a highly immunosuppressive tumor microenvironment (TME), invariably infiltrated by tumor-associated macrophages (TAMs). These TAMs resemble M2 macrophages, which promote tumor growth and suppress immune responses. GBM cells secrete extracellular vesicles (EVs) containing microRNA-25, which inhibits the cGAS-STING pathway and prevents TAMs from adopting a pro-inflammatory M1 phenotype. This study characterizes antimiR-25/cGAMP nanocomplexes (NCs) for potential therapeutic applications. A particle size analysis revealed a significant reduction upon complexation with antimiR-25, resulting in smaller, more stable nanoparticles. Stability tests across pH levels (4–6) and temperatures (25–37 °C) demonstrated their resilience in various biological environments. Biological assays showed that antimiR-25 NCs interacted strongly with transferrin (Tf), suggesting potential for blood–brain barrier passage. The use of cGAMP NCs activated the cGAS-STING pathway in macrophages, leading to increased type I IFN (IFN-β) production and promoting a shift from the M2 to M1 phenotype. The combined use of cGAMP and antimiR-25 NCs also increased the expression of markers involved in M1 polarization. These findings offer insights into optimizing antimiR-25/cGAMP NCs for enhancing immune responses in GBM.

4 June 2025 in ACS Applied Nano Materials
Verified
Journal Article
Open access
OMOliwia Majchrzak
Oliwia Majchrzak
AMAleksandra Makiej
Aleksandra Makiej
CSCarolina Lopes Silva
Carolina Lopes Silva
Olivier JordanOlivier Jordan
Olivier Jordan
Gerrit BorchardGerrit Borchard
Gerrit Borchard
Wojciech SmułekWojciech Smułek
Wojciech Smułek

25 February 2026 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
NONahide Zeren Arda Ozturk
Nahide Zeren Arda Ozturk
OMOliwia Majchrzak
Oliwia Majchrzak
GUGianluca Ulivi
Gianluca Ulivi
PKPetek Ballar Kirmizibayrak
Petek Ballar Kirmizibayrak
Gerrit BorchardGerrit Borchard
Gerrit Borchard
OOOzgen Ozer
Ozgen Ozer
Fully synthetic exosome-mimetics (FSEMs) represent a nature-inspired drug delivery system designed to replicate the key physicochemical and biological properties of natural exosomes, while offering the potential to address limitations in scalability and reproducibility associated with natural exosomes. In this study, we prepared FSEMs at the laboratory scale. We loaded them with (-)-epigallocatechin-3-gallate (EGCG) and microRNA-23a (miR-23a), aiming to co-deliver therapeutic small molecules and nucleic acids for the treatment of melanoma. FSEMs were fabricated using three methods: thin-film hydration, ethanol injection, and microfluidics. They were surface-functionalized with either CD9, a tetraspanin involved in membrane fusion, or TSP-1, an adhesion protein promoting cellular interactions. Through physicochemical characterization via dynamic light scattering, we found that FSEMs were ∼ 100 nm in size, of low polydispersity (∼0.2) and showed a negative zeta potential (∼-55 mV). Both EGCG and miR-23a were efficiently encapsulated. SDS-PAGE analysis confirmed successful protein incorporation and correct positioning. In vitro release studies showed minimal premature leakage, supporting their suitability for cellular uptake-mediated delivery. When tested on melanoma cells (MDA-MB-435) and progenitor human dermal fibroblasts (FE002-SK2), FSEMs selectively killed melanoma cells while sparing fibroblasts. Importantly, EGCG within FSEMs was more effective than the free compound. Compared to conventional DOTAP-based liposomes, FSEMs were more selective and induced less off-target cytotoxicity. This study presents a proof-of-concept for fully synthetic, protein-functionalized FSEMs as dual carriers for both chemical and gene-based agents, offering a safer and potentially more effective alternative to traditional cationic liposomes. These results lay the groundwork for future in vivo validation and translational cancer research.

20 March 2026 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
OMOliwia Majchrzak
Oliwia Majchrzak
CSCarolina Lopes Silva
Carolina Lopes Silva
STStoyan Tankov
Stoyan Tankov
JBJulien Boccard
Julien Boccard
SRSerge Rudaz
Serge Rudaz
Gerrit BorchardGerrit Borchard
Gerrit Borchard
Triple-negative breast cancer (TNBC) remains a highly aggressive disease with limited therapeutic options, and metastasis is the leading cause of patient mortality which highlights a major unmet medical need. Nevertheless, the mechanisms regulating metastatic progression remain poorly understood. Extracellular vesicles (EVs) have recently emerged as key mediators of the intercellular communication. Ubiquitously secreted, these nanoparticles provide a convenient and informative glimpse into cellular physiology given that their molecular composition shall reflect the state of their parent cell. Therefore, in this study, we aim to show that lipid profiles of EVs may differentiate malignant from non-malignant cells and to reveal biomarkers associated with TNBC. For this reason, we investigated the lipid composition of EVs released by cancer cells (MDA-MB-231, MDA-MB-453 and MDA-MB-468 representing TNBC) and non-malignant (MCF10A) human breast epithelial cells, with the goal of highlighting specific lipid profiles that might serve as potential biomarkers for TNBC. EV isolation and characterization were performed in accordance with MISEV2023 guidelines, while lipidomic profiling was carried out using an untargeted liquid chromatography and high-resolution mass spectrometry approach. We annotated over 500 complex lipid species. Multivariate analysis was used to explore major trends in the dataset, separating EVs derived from cancerous and non-cancerous cells and capturing differences among TNBC-derived EVs, reflecting their distinct genetic background. Further supervised modelling revealed distinct TNBC lipidomic signatures including phosphatidylcholines with alkyl chains of C18:0_C19:1, C20:1_C22:5, C18:1_C22:6 or C15:0_C22:5, C17:0_C20:3 and phosphatidylserine C32:0 which consistently emerged as shared lipid species across TNBC-derived EVs, highlighting their potential as biomarkers for the detection of TNBC. Furthermore, we highlighted lipid subsets specific to each of the investigated TNBC's source of EVs for in-depth molecular subtyping of TNBC.